Startseite
English
Erweiterte Suche
Durchblättern nach ...
Publikationen im Überblick
Ansprechpartner
Hilfe
DOI
PMC
 |
|
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Metabolic dysfunction-associated steatotic liver disease and extrahepatic gastrointestinal cancers.
Metabolism 160:156014 (2024)
Metabolic dysfunction-associated steatotic liver disease (MASLD) poses a significant and ever-increasing health and economic burden worldwide. Substantial epidemiological evidence shows that MASLD is a multisystem disease that is associated not only with liver-related complications but is also associated with an increased risk of developing cardiometabolic comorbidities and extrahepatic cancers (principally gastrointestinal [GI] cancers). GI cancers account for a quarter of the global cancer incidence and a third of cancer-related deaths. In this narrative review, we provide an overview of the literature on (a) the epidemiological data on the risk of non-liver GI cancers in MASLD, (b) the putative mechanisms by which MASLD (and factors linked with MASLD) may increase this risk, and (c) the possible pharmacotherapies beneficially affecting both MASLD and extrahepatic GI cancer risk. There are multiple potential pathophysiological mechanisms by which MASLD may increase extrahepatic GI cancer risk. Although further studies are needed, the current evidence supports a possible extrahepatic carcinogenic role for MASLD, regardless of obesity and diabetes status, thus highlighting the potential role of tailoring cancer screening for individuals with MASLD. Although there are conflicting data in the literature, aspirin, statins and metformin appear to exert some chemo-preventive effects against GI cancer.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten
[➜Einloggen]
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Review
Schlagwörter
Extrahepatic Cancers ; Gastrointestinal Cancers ; Masld ; Metabolic Dysfunction-associated Steatotic Liver Disease ; Nonalcoholic Fatty Liver Disease; Nonsteroidal Antiinflammatory Drugs; Digestive-tract Cancers; Aspirin Use; Colorectal-cancer; Reduced Risk; Fetuin-a; Pancreatic-cancer; Extracellular Vesicles; Barretts-esophagus; Bariatric Surgery
ISSN (print) / ISBN
0026-0495
e-ISSN
1532-8600
Zeitschrift
Metabolism: clinical and experimental
Quellenangaben
Band: 160,
Artikelnummer: 156014
Verlag
Elsevier
Verlagsort
1600 John F Kennedy Boulevard, Ste 1800, Philadelphia, Pa 19103-2899 Usa
Nichtpatentliteratur
Publikationen
Begutachtungsstatus
Peer reviewed